Induction of resistance to etoposide and adriamycin in a human glioma cell line treated with antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid of deoxyribonucleic acid topoisomerase IIα

Neurologia Medico-Chirurgica

Volumn 37, Issue 9, 1997, Pages 655-662

  Kuriyama, Mitsuo ^a   Tsutsui, Kimiko ^a   Tsutsui, Ken ^a   Ono, Yasuhiro ^a   Tamiya, Takashi ^a   Matsumoto, Kengo ^a   Furuta, Tomohisa ^a   Ohmoto, Takashi ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Antisense oligodeoxynucleotides; Deoxyribonucleic acid topoisomerase II; Glioma; Multidrug resistance

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; MESSENGER RNA;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GLIOMA CELL; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; TRANSCRIPTION INITIATION;

EID: 0030928771     PISSN: 03872572     EISSN: None     Source Type: Journal    
DOI: 10.2176/nmc.37.655     Document Type: Article

References (32)

1. Adachi Y, Luke M, Laemmli UK: Chromosome assembly in vitro: topoisomerase II is required for condensation. Cell 64: 137-148, 1991
2. Andoh T: [Biological functions of DNA topoisomerases]. Gan To Kagaku Ryoho 18: 1543-1549, 1991 (Jpn)
3. Chamberlain MC: Recurrent brainstem gliomas treated with oral VP-16. J Neurooncol 15: 133-139, 1993
4. Chen AY, Liu LF: DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34: 191-218, 1994
5. Chung TD, Drake FH, Tan KB, Per SR, Crooke ST, Mirabelli CK: Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci U S A 86: 9431-9435, 1989
6. Danks MK, Yalowich JC, Beck WT: Atypical multiple drug resistance in a human leukemia cell line selected for resistance to teniposide (VM-26). Cancer Res 47: 1297-1301, 1987
7. DiNardo S, Voelkel K, Sternglanz R: DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proc Natl Acad Sci U S A 81: 2616-2620, 1984
8. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK: Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28: 8154-8160, 1989
9. Eder JJ, Chan VT, Ng SW, Rizvi NA, Zacharoulis S, Teicher BA, Schnipper LE: DNA topoisomerase II alpha expression is associated with alkylating agent resistance. Cancer Res 55: 6109-6116, 1995
10. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME: High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A 89: 3070-3074, 1992
11. Harker WG, Slade DL, Drake FH, Parr RL: Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 30: 9953-9961, 1991
12. Hoshino T, Nagashima T, Murovic JA, Wilson CB, Davis RL: Proliferative potential of human meningiomas of the brain. A cell kinetics study with bromodeoxyuridine. Cancer 58: 1466-1472, 1986
13. Hsiang YH, Wu HY, Liu LF: Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 48: 3230-3235, 1988
14. Liu LF, Wang JC: Supercoiling of the DNA template during transcription. Proc Natl Acad Sci U S A 84: 7024-7027, 1987
15. Matsumoto Y, Fujiwara T, Honjou Y, Sasaoka N, Tsuchida T, Nagao S: Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: Characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11. J Surg Oncol 53: 97-103, 1993
16. Matsuo K, Kohno K, Takano H, Sato S, Kiue A, Kuwano M: Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines. Cancer Res 50: 5819-5824, 1990
17. Minato K, Kanzawa F, Nishio K, Nakagawa K, Fujiwara Y, Saijo N: Characterization of an etoposide-resistant human small-cell lung cancer cell line. Cancer Chemother Pharmacol 26: 313-317, 1990
18. Nakagawa H, Fujita T, Kubo S, Tsuruzono K, Yamada M, Tokiyoshi K, Miyawaki Y, Kanayama T, Kadota T, Hayakawa T: Selective intra-arterial chemotherapy with a combination of etoposide and cisplatin for malignant gliomas: preliminary report. Surg Neurol 41: 19-27, 1994
19. Nikkhah G, Tonn JC, Hoffmann O, Kraemer HP, Darling JI, Schonmayr R: The MTT assay for chemosensitivity testing of human tumors of the central nervous system. J Neurooncol 13: 1-11, 1992
20. Prosperi E, Sala E, Negri C, Oliani C, Supino R, Astraldi RG, Bottiroli G: Topoisomerase II alpha and beta in human tumor cells grown in vitro and in vivo. Anticancer Res 12: 2093-2099, 1992
21. Satoh M, Kloth DM, Kadhim SA, Chin JL, Naganuma A, Imura N, Cherian MG: Modulation of both cisplatin nephrotoxicity and drug resistance in murine bladder tumor by controlling metallothionein synthesis. Cancer Res 53: 1829-1832, 1993
22. Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH: Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 54: 152-158, 1994
23. Shimoyama Y, Kubota T, Watanabe M, Ishibiki K, Abe O: Predictability of in vivo chemosensitivity by in vitro MTT assay with reference to the clonogenic assay. J Surg Oncol 41: 12-18, 1989
24. Tirelli U, D'Incalci M, Canetta R, Tumolo S, Franchin G, Veronesi A, Galligioni E, Trovo MG, Rossi C, Grigoletto E: Etoposide (VP-16-213) in malignant brain tumors: a phase II study. J Clin Oncol 2: 432-437, 1984
25. Tsutsui K, Tsutsui K, Okada S, Watanabe M, Shohmori T, Seki S, Inoue Y: Molecular cloning of partial cDNAs for rat topoisomerase II isoforms and their differential expression in brain development. J Biol Chem 268: 19076-19083, 1993
26. Uemura T, Ohkura H, Adachi Y, Morino K, Shiozaki K, Yanagida M: DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell 50: 917-925, 1987
27. Wagner RW: Gene inhibition using antisense oligodeoxynucleotides. Nature 372: 333-335, 1994
28. Wang JC: DNA topoisomerases. Annu Rev Biochem 54: 665-697, 1985
29. Wang JC: Recent studies of DNA topoisomerases. Biochim Biophys Acta 909: 1-9, 1987
30. Webb CD, Latham MD, Lock RB, Sullivan DM: Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res 51: 6543-6549, 1991
31. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH: Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 2: 209-214, 1991
32. Wu HY, Shyy SH, Wang JC, Liu LF: Transcription generates positively and negatively supercoiled domains in the template. Cell 53: 433-440, 1988